If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCom.int.bk.regs Regulatory News (CBKD)

Share Price Information for Com.int.bk.regs (CBKD)

Share Price is delayed by 15 minutes
Get Live Data
2.60    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.02 (0.769%)
Market Cap: $8.58b
CBKD Live PriceLast checked at - London Stock Exchange

Intraday Com.int.bk.regs Share Chart

  • This share is an international stock.

3rd Quarter Results

3 Nov 2023 07:05

RNS Number : 2593S
Commercial Intnl Bank (Egypt) SAE
03 November 2023
Β 

Commercial International Bank (Egypt) S.A.E.

Separate Financial Statements

Β 

September 30, 2023

Β 

Β 

Β 

Condensed Separate Interim Statement of Financial Position as at September 30, 2023

Β 

Notes

Sep. 30, 2023

Β 

Dec. 31, 2022

EGP Thousands

Β 

EGP Thousands

Β 

Β 

Assets

Β 

Β 

Β 

Cash and balances at the central bank

8

59,818,535

Β 

47,384,574

Due from banks

9

276,244,051

Β 

133,766,196

Loans and advances to banks, net

11

-

Β 

2,978,197

Loans and advances to customers, net

12

222,326,692

Β 

192,621,288

Derivative financial instruments

1,647,485

Β 

1,939,961

Financial investments

Β 

Β 

Β 

- Financial Assets at Fair Value through OCI

13

188,243,712

Β 

202,916,225

- Financial Assets at Amortized cost

13

38,686,046

Β 

34,178,753

- Investments in associates and subsidiaries

14

694,633

Β 

1,074,250

Non current assets held for sale

27

159,828

Β 

-

Other assets

15

17,327,838

Β 

14,454,868

Deferred tax assets

1,137,342

Β 

24,240

Property and equipment

16

2,456,340

Β 

2,304,513

Total assets

Β 

808,742,502

Β 

633,643,065

Liabilities and equity

Β 

Β 

Β 

Liabilities

Β 

Β 

Β 

Due to banks

17

19,030,415

Β 

3,475,848

Due to customers

18

665,894,926

Β 

530,124,905

Derivative financial instruments

99,911

Β 

219,752

Current income tax liabilities

6,993,454

Β 

3,051,583

Other liabilities

19

15,475,422

Β 

11,549,472

Issued debt instruments

20

3,071,834

Β 

2,456,607

Other loans

10,387,714

Β 

7,978,975

Other provisions

21

10,510,696

Β 

7,065,292

Total liabilities

Β 

731,464,372

Β 

565,922,434

Equity

Β 

Β 

Β 

Issued and paid up capital

30,195,010

Β 

29,825,134

Reserves

23,549,307

Β 

19,502,716

Reserve for employee stock ownership plan (ESOP)

1,339,443

Β 

1,895,435

Retained earnings *

22,194,370

Β 

16,497,346

Total equity and net profit for the period / year

Β 

77,278,130

Β 

67,720,631

Total liabilities and equity

Β 

808,742,502

Β 

633,643,065

The accompanying notes are an integral part of these financial statements.

Β 

(Limited review report attached)

Β 

*

Including net profit for the current period

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Condensed Separate Interim Income Statement for the period ended September 30, 2023

Β 

Β 

Β 

Β 

Β 

Β 

Last 9 Months

Β 

Last 9 Months

Notes

Sep. 30, 2023

Β 

Sep. 30, 2022

EGP Thousands

Β 

EGP Thousands

Β 

Β 

Interest and similar income

72,741,395

Β 

38,761,627

Interest and similar expense

(35,154,201)

Β 

(17,050,977)

Net interest income

Β 

37,587,194

Β 

21,710,650

Β 

Β 

Fee and commission income

6,540,630

Β 

3,900,488

Fee and commission expense

(2,590,207)

Β 

(1,730,066)

Net fee and commission income

Β 

3,950,423

Β 

2,170,422

Β 

Β 

Dividend income

100,244

Β 

64,372

Net trading income

5

3,146,544

Β 

1,431,729

Profits (Losses) on financial investmentsΒ 

13.1

(1,256,233)

Β 

1,096,850

Administrative expenses

(6,304,022)

Β 

(5,024,897)

Other operating (expenses) income

6

(5,293,795)

Β 

(3,399,057)

Impairment release (charges) for credit losses

(1,248,897)

Β 

(262,606)

Profit before income tax

Β 

30,681,458

Β 

17,787,463

Β 

Β 

Income tax expense

25

(9,540,541)

Β 

(4,984,283)

Deferred tax assets (Liabilities)

25

591,159

Β 

(597,258)

Net profit for the period

Β 

21,732,076

Β 

12,205,922

Β 

Β 

Earnings per share

7

Β 

Β 

Basic

6.41

Β 

3.62

Diluted

6.34

Β 

3.58

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Condensed Separate Interim statement of Comprehensive Income for the period ended September 30, 2023

Β 

Last 9 Months

Β 

Last 9 Months

Sep. 30, 2023

Β 

Sep. 30, 2022

EGP Thousands

Β 

EGP Thousands

Β 

Β 

Net profit for the period

21,732,076

Β 

12,205,922

Β 

Β 

Change in fair value of Financial invesments measured at fair value through comprehensive income after tax

(9,611,703)

Β 

(13,128,801)

Transferred to RE from financial assets at fair value through comprehensive income

(95,308)

Β 

(4,128)

Effect of ECL in fair value of debt instruments measured at fair value through comprehensive income

197,888

Β 

233,717

Total comprehensive income for the period

Β 

12,222,953

Β 

(693,290)

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Condensed Separate Interim Cash flows for the period ended September 30 2023

Β 

Β 

Notes

Sep. 30, 2023

Β 

Sep. 30, 2022

EGP Thousands

Β 

EGP Thousands

Β 

Β 

Cash flow from operating activities

Β 

Β 

Β 

Profit before income tax

30,681,458

Β 

17,787,463

Adjustments to reconcile profits to net cash provided by operating activities

Β 

Β 

Β 

Fixed assets depreciation

16

636,285

654,220

Impairment (Released) charge for credit losses (Loans and advances to customers and banks)

1,088,174

(16,255)

Other provisions charged ( Released )

21

2,350,347

1,803,863

Impairment (Released) charge for credit losses (due from banks)

(49,019)

849

Impairment (Released) charge for credit losses (financial investments)

209,742

278,012

Impairment (Released) charge for other assets

14,347

(277,768)

Exchange revaluation differences for financial assets at fair value through OCI and AC

(5,409,592)

(3,745,045)

Utilization of other provisions

21

(1,608)

(1,857)

Other provisions no longer used

21

-

(101)

Exchange revaluation differences of other provisions

21

1,096,665

333,425

profits from selling property and equipment

(194)

(2,192)

profits from selling financial investments at fair value through OCI

13.1

(149,012)

(1,096,850)

Losses (Profits) from selling investments in associates

13.1

(7,466)

-

Shares based payments

608,250

579,653

Impairment (Released) charges of investments in associates and subsidiaries

13.1

1,412,711

-

Operating profits before changes in operating assets and liabilities

Β 

32,481,088

Β 

16,297,417

Β 

Β 

Net decrease / increase in assets and liabilities

Β 

Β 

Β 

Due from banks

5,142,259

845,633

Financial assets at fair value through P&L

-

240,987

Derivative financial instruments

172,635

(947,116)

Loans and advances to banks and customers

11 - 12

(27,805,660)

(33,520,003)

Other assets

(2,507,984)

1,242,254

Due to banks

17

15,554,567

841,125

Due to customers

18

135,770,021

91,483,674

Current income tax obligations paid

(2,547,087)

(2,305,911)

Other liabilities

874,366

(310,752)

Net cash generated from (used in) operating activities

Β 

157,134,205

Β 

73,867,308

Β 

Β 

Cash flow from investing activities

Β 

Β 

Β 

Proceeds from investments in associates.

2,119

-

Payments for investment in subsidiaries

(1,216,022)

(59,900)

Payment for purchases of property, equipment and branches construction

(1,162,819)

(542,743)

Proceeds from selling property and equipment

194

2,192

Proceeds from redemption of financial assets at amortized cost

5,278,030

6,569,803

Payment for purchases of financial assets at amortized cost

(9,178,811)

(18,239,332)

Payment for purchases of financial assets at fair value through OCI

(65,109,765)

(114,918,927)

Proceeds from selling financial assets at fair value through OCI

76,347,190

73,463,225

Net cash generated from (used in) investing activities

Β 

4,960,116

Β 

(53,725,682)

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Condensed Separate Interim Cash flows for the period ended September 30, 2023 (Cont.)

Β 

Β 

Sep. 30, 2023

Β 

Sep. 30, 2022

EGP Thousands

Β 

EGP Thousands

Β 

Β 

Cash flow from financing activities

Β 

Β 

Β 

Other loans

2,408,739

1,116,344

Dividends paid

(3,738,888)

(4,410,322)

Issued debt instruments

615,227

382,977

Capital increase

369,876

122,716

Net cash generated from (used in) financing activities

Β 

(345,046)

Β 

(2,788,285)

Β 

Β 

Β 

Β 

Net (decrease) increase in cash and cash equivalent during the period

161,749,275

17,353,341

Beginning balance of cash and cash equivalent

92,895,143

60,891,899

Cash and cash equivalent at the end of the period

Β 

254,644,418

Β 

78,245,240

Β 

Β 

Cash and cash equivalent comprise:

Β 

Β 

Β 

Cash and balances at the central bank

59,818,535

43,776,754

Due from banks

276,244,266

90,419,482

Treasury bills

10

71,507,826

Β 

87,119,766

Obligatory reserve balance with CBE

(52,853,882)

Β 

(38,022,832)

Due from banks with maturity more than three months

(29,659,932)

(22,949,758)

Treasury bills with maturity more than three months

(70,412,395)

(82,098,172)

Total cash and cash equivalent

Β 

254,644,418

Β 

78,245,240

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Condensed Separate Interim statement of changes in shareholders' equity

Β 

Sep. 30, 2022

Issued and paid up capital

Legal reserve

General reserve

General risk reserve

Capital reserve

Reserve for financial assets at fair value through OCI

Banking risks reserve

Retained earnings

Reserve for employee stock ownership plan

Total

Β 

Beginning Balance at 1 Januray 2022

19,702,418

3,293,074

28,260,532

1,549,445

16,000

639,231

9,141

13,783,935

1,674,392

68,928,168

Capital increase

10,122,716

-

(10,000,000)

-

-

-

-

-

-

122,716

Transferred to reserves

-

670,872

8,836,326

-

2,947

-

-

(9,007,223)

(502,922)

-

Dividend paid

-

-

-

-

-

-

-

(4,410,322)

-

(4,410,322)

Net profit for the period

-

-

-

-

-

-

-

12,205,922

-

12,205,922

Transferred to RE from financial assets at fair value through OCI

-

-

-

-

-

(4,128)

-

4,128

-

-

Net unrealised gain/(loss) on financial assets at fair value through OCI after tax

-

-

-

-

-

(13,128,801)

-

-

-

(13,128,801)

Transferred (from) to bank risk reserve

-

-

-

-

-

-

2,840

(2,840)

-

-

Effect of ECL in fair value of debt instruments measured at fair value through OCI

-

-

-

-

-

233,717

-

-

-

233,717

Cost of employees stock ownership plan (ESOP)

-

-

-

-

-

-

-

-

579,653

579,653

Β Balance at 30 September 2022

29,825,134

3,963,946

27,096,858

1,549,445

18,947

(12,259,981)

11,981

12,573,600

1,751,123

64,531,053

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Sep. 30, 2023

Issued and paid up capital

Legal reserve

General reserve

General risk reserve

Capital reserve

Reserve for financial assets at fair value through OCI

Banking risks reserve

Retained earnings

Reserve for employee stock ownership plan

Total

Β 

Β 

Β 

Β 

Β 

Beginning Balance at 1 Januray 2023

29,825,134

3,963,946

27,096,858

1,549,445

18,947

(13,138,461)

11,981

16,497,346

1,895,435

67,720,631

Capital increase

369,876

-

-

-

-

-

-

-

-

369,876

Transferred to reserves

-

806,408

12,743,849

-

2,208

-

-

(12,388,223)

(1,164,242)

-

Dividend paid

-

-

-

-

-

-

-

(3,738,888)

-

(3,738,888)

Net profit for the period

-

-

-

-

-

-

-

21,732,076

-

21,732,076

Transferred to RE from financial assets at fair value through OCI

-

-

-

-

-

(95,308)

-

95,308

-

-

Net unrealised gain/(loss) on financial assets at fair value through OCI after tax

-

-

-

-

-

(9,611,703)

-

-

-

(9,611,703)

Transferred (from) to banking risk reserve

-

-

-

-

-

-

3,249

(3,249)

-

-

Effect of ECL in fair value of debt instruments measured at fair value through OCI

-

-

-

-

-

197,888

-

-

-

197,888

Cost of employees stock ownership plan (ESOP)

-

-

-

-

-

-

-

-

608,250

608,250

Β Balance at 30 September 2023

30,195,010

4,770,354

39,840,707

1,549,445

21,155

(22,647,584)

15,230

22,194,370

1,339,443

77,278,130

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
QRTUPGMPGUPWGRP
Date   Source Headline
31st Oct 20083:41 pmRNSPrice Monitoring Extension
24th Oct 20083:41 pmRNSPrice Monitoring Extension
20th Oct 20083:40 pmRNSPrice Monitoring Extension
10th Oct 20083:40 pmRNSPrice Monitoring Extension
9th Oct 20083:47 pmRNSSecond Price Monitoring Extn
9th Oct 20083:41 pmRNSPrice Monitoring Extension
2nd Oct 20083:46 pmRNSSecond Price Monitoring Extn
2nd Oct 20083:40 pmRNSPrice Monitoring Extension
1st Oct 20083:45 pmRNSSecond Price Monitoring Extn
1st Oct 20083:40 pmRNSPrice Monitoring Extension
30th Sep 20083:47 pmRNSSecond Price Monitoring Extn
30th Sep 20083:41 pmRNSPrice Monitoring Extension
17th Sep 200811:57 amRNSResponse to Market Rumour
8th Sep 20088:54 amRNSDirectorate Change
29th Aug 20083:40 pmRNSPrice Monitoring Extension
18th Aug 20083:45 pmRNSSecond Price Monitoring Extn
18th Aug 20083:40 pmRNSPrice Monitoring Extension
13th Aug 20087:00 amRNSDirectorate Change
13th Aug 20087:00 amRNSInterim Management Statement
13th Aug 20087:00 amRNSInterim Results
8th Aug 20083:40 pmRNSPrice Monitoring Extension
7th Aug 20083:40 pmRNSPrice Monitoring Extension
4th Aug 20088:50 amRNSHolding(s) in Company
16th Jul 20087:10 amRNSRe: Stock Dividend
30th Jun 20087:00 amRNSpress release
14th May 20087:36 amRNSAAIB Merger
12th May 20083:48 pmRNS1st Quarter Results
6th May 20083:45 pmRNSSecond Price Monitoring Extn
6th May 20083:40 pmRNSPrice Monitoring Extension
30th Apr 20082:01 pmRNSChanges in IR Team
18th Mar 20082:55 pmRNSAGM Statement
17th Mar 20087:00 amRNSFormal Notice
25th Feb 20087:00 amRNSFurther re Final Results
25th Feb 20087:00 amRNSFinal Results
25th Feb 20087:00 amRNSProposed Stock Dividend
12th Nov 20077:04 amRNS3rd Quarter Results
1st Oct 20077:02 amRNSStatement re Possible Offer
8th Aug 20077:00 amRNSInterim Results
31st May 20073:44 pmRNSPrice Monitoring Extension
14th May 20077:00 amRNS1st Quarter Results
15th Mar 200712:41 pmRNSDividend Declaration
6th Feb 20074:13 pmRNSFinal Results - Replacement
6th Feb 20078:56 amRNSFinal Results
15th Jan 20078:00 amRNSStatement re. Press Comment
6th Nov 20067:00 amRNS3rd Quarter Results
30th Oct 20069:44 amRNSStrategic Alliance
17th Oct 20061:08 pmRNSFormal Notice
21st Aug 20067:00 amRNSRe Alliance
17th Aug 20068:48 amRNSIssue of Equity
8th Aug 20062:02 pmRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.